In conclusion, our results suggest that A1AT can reverse the outer retinal alterations that occur during early AMD and can also ameliorate the severe wet AMD retinal phenotypes by inhibiting the pathological VEGF increase and CNV progression. This evidence concerns the gene VEGFA and age-related macular degeneration.